vs
FVCBankcorp, Inc.（FVCB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是FVCBankcorp, Inc.的1.8倍（$30.3M vs $16.9M），FVCBankcorp, Inc.同比增速更快（4377.5% vs 43.0%），FVCBankcorp, Inc.自由现金流更多（$23.8M vs $-52.8M），过去两年FVCBankcorp, Inc.的营收复合增速更高（586.6% vs 39.4%）
FVCBankcorp是总部位于美国弗吉尼亚州的银行控股公司，旗下运营社区银行FVCbank，面向大西洋中部地区的中小企业、专业人士及个人客户提供存款、贷款、按揭、财富管理等各类个人及商业银行金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FVCB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$16.9M
营收增速更快
FVCB
高出4334.5%
43.0%
自由现金流更多
FVCB
多$76.6M
$-52.8M
两年增速更快
FVCB
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.9M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 43.7% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 4377.5% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.31 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVCBRGNX
| Q4 25 | $16.9M | $30.3M | ||
| Q3 25 | $416.0K | $29.7M | ||
| Q2 25 | $15.8M | $21.4M | ||
| Q1 25 | $382.0K | $89.0M | ||
| Q4 24 | $378.0K | $21.2M | ||
| Q3 24 | $412.0K | $24.2M | ||
| Q2 24 | $415.0K | $22.3M | ||
| Q1 24 | $359.0K | $15.6M |
净利润FVCBRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $5.6M | $-61.9M | ||
| Q2 25 | $5.7M | $-70.9M | ||
| Q1 25 | $5.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $4.7M | $-59.6M | ||
| Q2 24 | $4.2M | $-53.0M | ||
| Q1 24 | $1.3M | $-63.3M |
毛利率FVCBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FVCBRGNX
| Q4 25 | 43.7% | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | 45.9% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率FVCBRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 1341.1% | -208.3% | ||
| Q2 25 | 36.0% | -331.8% | ||
| Q1 25 | 1352.1% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 1133.3% | -246.3% | ||
| Q2 24 | 1001.2% | -237.7% | ||
| Q1 24 | 373.3% | -405.4% |
每股收益（稀释后）FVCBRGNX
| Q4 25 | $0.31 | $-1.30 | ||
| Q3 25 | $0.31 | $-1.20 | ||
| Q2 25 | $0.31 | $-1.38 | ||
| Q1 25 | $0.28 | $0.12 | ||
| Q4 24 | $0.27 | $-0.99 | ||
| Q3 24 | $0.25 | $-1.17 | ||
| Q2 24 | $0.23 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $253.6M | $102.7M |
| 总资产 | $2.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FVCBRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益FVCBRGNX
| Q4 25 | $253.6M | $102.7M | ||
| Q3 25 | $249.8M | $161.5M | ||
| Q2 25 | $243.2M | $213.7M | ||
| Q1 25 | $242.3M | $274.2M | ||
| Q4 24 | $235.4M | $259.7M | ||
| Q3 24 | $230.8M | $301.4M | ||
| Q2 24 | $226.5M | $348.3M | ||
| Q1 24 | $220.7M | $390.7M |
总资产FVCBRGNX
| Q4 25 | $2.3B | $453.0M | ||
| Q3 25 | $2.3B | $525.2M | ||
| Q2 25 | $2.2B | $581.0M | ||
| Q1 25 | $2.2B | $490.9M | ||
| Q4 24 | $2.2B | $466.0M | ||
| Q3 24 | $2.3B | $519.1M | ||
| Q2 24 | $2.3B | $569.4M | ||
| Q1 24 | $2.2B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $23.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 140.7% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FVCBRGNX
| Q4 25 | $23.9M | $-52.3M | ||
| Q3 25 | $7.6M | $-56.0M | ||
| Q2 25 | $3.3M | $-49.3M | ||
| Q1 25 | $5.4M | $33.6M | ||
| Q4 24 | $18.2M | $-31.6M | ||
| Q3 24 | $4.7M | $-40.5M | ||
| Q2 24 | $1.6M | $-45.5M | ||
| Q1 24 | $7.2M | $-55.5M |
自由现金流FVCBRGNX
| Q4 25 | $23.8M | $-52.8M | ||
| Q3 25 | $7.6M | $-56.5M | ||
| Q2 25 | $3.3M | $-49.7M | ||
| Q1 25 | $5.4M | $32.6M | ||
| Q4 24 | $18.1M | $-32.7M | ||
| Q3 24 | $4.6M | $-40.9M | ||
| Q2 24 | $1.5M | $-46.0M | ||
| Q1 24 | $7.1M | $-56.0M |
自由现金流率FVCBRGNX
| Q4 25 | 140.7% | -174.0% | ||
| Q3 25 | 1818.0% | -189.9% | ||
| Q2 25 | 20.8% | -232.8% | ||
| Q1 25 | 1413.6% | 36.6% | ||
| Q4 24 | 4786.0% | -154.2% | ||
| Q3 24 | 1121.8% | -168.9% | ||
| Q2 24 | 361.2% | -206.2% | ||
| Q1 24 | 1988.3% | -358.5% |
资本支出强度FVCBRGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 4.2% | 1.2% | ||
| Q4 24 | 37.3% | 5.1% | ||
| Q3 24 | 14.1% | 1.3% | ||
| Q2 24 | 12.8% | 2.1% | ||
| Q1 24 | 3.9% | 3.6% |
现金转化率FVCBRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVCB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
